Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Phenylephrine

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Neosynephrine ® - Phenylephrine (opens in a new tab)Original source URL: https://globalrph.com/dilution/neosynephrine-phenylephrine/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/neosynephrine-phenylephrine/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:47:39.168254+00:00
Source location
div.post-content
Packaged content SHA-256
e2ef16dd8abd2614797adc70a00320bc721a45adc6e769d4243ec451d9611261
Original response SHA-256
6e6bb1c87fd9589ba50ebffd7aad2029ac1cfaa86f7f91fd4053526fb7c790de
Source body SHA-256
d92b6ff0260677cd0cbe2e8f7a3bb8fa03bd98b507b94fe478ca6422fa0ec9b1

Phenylephrine (Neosynephrine ®)

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

NS (preferred) , D5W (less support)

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

Standard Dilutions:
[Concentration: 0.1 mg/ml - 0.9NS. Stability 14 days at room temperature ] 1:
[25 mg] [250 ml] [Titrate] or [50 mg] [500 ml] [Titrate]OR[Concentration: 0.2 mg/ml -0.9NS. Stability 14 days RT-possibly up to 60 days RT]1,2:
[50 mg] [250 ml] [Titrate] or [100 mg] [500 ml] [Titrate]
---------------------Other:
Minimum dilution:
[Concentration: 0.4 mg/ml -0.9NS. Stability 60 days RT]2:
[40 mg] [100 ml] [Titrate]

Package insert:
D5W or 0.9NS - stability unknown3.
[10 mg] [500 ml] [Titrate]

Reference data for updated dilution standards:
1] Gupta VD. Chemical Stability of Phenylephrine Hydrochloride After Reconstitution in 0.9% Sodium Chloride Injection for Infusion. Int J Pharm Compd. 2004 March-April;8(2):153-155.

Abstract
"The chemical stability of phenylephrine hydrochloride (0.2 and 0.1 mg/mL) in 0.9% sodium chloride injection stored in polyvinyl chloride bags was studied at 25 deg C by means of a stability-indicating high-performance liquid chromatographic assay method. The concentrations of the drug were directly related to peak heights, and the percent relative standard deviation based on five injections was 1.0. The excipients present in the injection did not interfere with the assay procedure. The products of decomposition separated from the intact drug. At both concentrations (0.2 and 0.1 mg/mL), the loss in potency was less than 1.0% after 14 days of storage at room temperature. The pH value of the 0.2-mg/mL injection decreased from 4.3 to 4.0 after 14 days of storage, and the pH value of the 0.1-mg/mL injection decreased from 4.4 to 4.2.The physical appearance of the injection did not change."

2] Jansen JJ, Oldland AR, Kiser TH. Evaluation of phenylephrine stability in polyvinyl chloride bags. Hosp Pharm. 2014 May;49(5):455-7. doi: 10.1310/hpj4905-455.

Abstract
"PURPOSE:
Phenylephrine hydrochloride (HCl) is commonly used to maintain adequate blood pressure during shock and shocklike states. Phenylephrine is prepared in concentrated stock vials that require further dilution prior to administration. This study evaluated the physical and chemical stability of phenylephrine in extemporaneously prepared polyvinyl chloride (PVC) bags.
METHODS:
Phenylephrine HCl 10 mg/mL solution was diluted with 0.9% sodium chloride for injection to final concentrations of 200 mcg/mL and 400 mcg/mL and stored at room temperature (23°C-25°C) exposed to fluorescent light. Stability of phenylephrine HCl was evaluated by high-performance liquid chromatography on days 0, 7, 14, 21, 30, 45, and 60.
RESULTS:
Phenylephrine HCl 200 and 400 mcg/mL solutions in PVC bags were physically stable during the entire 60-day study period. Phenylephrine HCl retained > 95% of the original concentration.
CONCLUSION:
Phenylephrine HCl diluted to 200 or 400 mcg/mL with 0.9% sodium chloride for injection is both physically and chemically stable for a period of 60 days with ≤5% degradation when stored at room temperature and exposed to fluorescent lighting."

3] Product Information (current packaging): PHENYLEPHRINE HYDROCHLORIDE- phenylephrine hydrochloride injection. Baxter Healthcare Corporation, Deerfield, IL 60015; 2014.

Add 10 mg of the drug (1 mL of 1 percent solution) to 500 mL of Dextrose Injection, USP or Sodium Chloride Injection.

Central line required. Peripheral line may be used for short periods (Max concentration: 10mg/250 ml) while preparation for central line is underway.

Stability / Miscellaneous

Label: Do not Refrigerate.

(Alpha agonist). May be given IM,SC, IV push, or by continuous infusion. Treat mild/moderate hypotension, also PSVT.

IV infusion: usual initial rate: 0.1 to 0.18 mg/min (100 to 180mcg/min) (titrate). Usual maintenance rate: 40-60 mcg/min.

-[Lexi-Comp, Inc. (Lexi-Drugs); October 2014]:
Usual maximum dosing range reported: 0.4 to 9.1 mcg/kg/minute-[Micromedex (DRUGDEX® System) - accessed (12/2014)]:
Usual range: 0.5 to 6 mcg/kg/min IV continuous infusion, titrate to blood pressure goal; no increase in efficacy above 6 mcg/kg/min.

IV bolus therapy: usual dose: 0.5 mg [range: 0.1 to 1 mg (max)] repeat q10-15 min as needed.

PSVT: 0.5 mg rapid IV push, subsequent doses may be increased in increments of 0.1 to 0.2mg.
------
DESCRIPTION
Phenylephrine hydrochloride is a vasoconstrictor and pressor drug chemically related to epinephrine and ephedrine. Phenylephrine hydrochloride is a synthetic sympathomimetic agent in sterile form for parenteral injection.

CLINICAL PHARMACOLOGY
Phenylephrine hydrochloride produces vasoconstriction that lasts longer than that of epinephrine and ephedrine. Responses are more sustained than those to epinephrine, lasting 20 minutes after intravenous and as long as 50 minutes after subcutaneous injection. Its action on the heart contrasts sharply with that of epinephrine and ephedrine, in that it slows the heart rate and increases the stroke output, producing no disturbance in the rhythm of the pulse.

Phenylephrine is a powerful postsynaptic alpha-receptor stimulant with little effect on the beta receptors of the heart. In therapeutic doses, it produces little if any stimulation of either the spinal cord or cerebrum. A singular advantage of this drug is the fact that repeated injections produce comparable effects.

ADVERSE REACTIONS
Headache, reflex bradycardia, excitability, restlessness and rarely arrhythmias.

DOSAGE AND ADMINISTRATION
Phenylephrine Hydrochloride Injection is generally injected subcutaneously, intramuscularly, slowly intravenously or in dilute solution as a continuous intravenous infusion. In patients with paroxysmal supraventricular tachycardia and, if indicated, in case of emergency, Phenylephrine Hydrochloride Injection is administered directly intravenously. The dose should be adjusted according to the pressor response.

Mild or Moderate Hypotension
SUBCUTANEOUSLY OR INTRAMUSCULARLY: Usual dose, from 2 mg to 5 mg. Range, from 1 mg to 10 mg. Initial dose should not exceed 5 mg.

INTRAVENOUSLY: Usual dose, 0.2 mg. Range, from 0.1 mg to 0.5 mg. Initial dose should not exceed 0.5 mg.

Injections should not be repeated more often than every 10 to 15 minutes. A 5 mg intramuscular dose should raise blood pressure for one to two hours. A 0.5 mg intravenous dose should elevate the blood pressure for about 15 minutes.

Severe Hypotension and Shock - Including Drug-Related Hypotension
Blood volume depletion should always be corrected as fully as possible before any vasopressor is administered. When, as an emergency measure, intraaortic pressures must be maintained to prevent cerebral or coronary artery ischemia, phenylephrine can be administered before and concurrently with blood volume replacement.

Hypotension and occasionally severe shock may result from overdosage or idiosyncrasy following the administration of certain drugs, especially adrenergic and ganglionic blocking agents, rauwolfia and veratrum alkaloids and phenothiazines tranquilizers. Patients who receive a phenothiazine derivative as preoperative medication are especially susceptible to these reactions. As an adjunct in the management of such episodes, Phenylephrine Hydrochloride Injection is a suitable agent for restoring blood pressure.

Higher initial and maintenance doses of phenylephrine are required in patients with persistent or untreated severe hypotension or shock. Hypotension produced by powerful peripheral adrenergic blocking agents, chlorpromazine or pheochromocytomectomy may also require more intensive therapy.

Continuous Infusion:
Add 10 mg of the drug (1 mL of 1 percent solution) to 500 mL of Dextrose Injection, USP or Sodium Chloride Injection, USP (providing a 1:50,000 solution). To raise the blood pressure rapidly, start the infusion at about 100 mcg to 180 mcg per minute (based on 20 drops per mL this would be 100 to 180 drops per minute). When the blood pressure is stabilized (at a low normal level for the individual), a maintenance rate of 40 mcg to 60 mcg per minute usually suffices (based on 20 drops per mL this would be 40 to 60 drops per minute). If the drop size of the infusion system varies from the 20 drops per mL the dose must be adjusted accordingly.

If a prompt initial pressor response is not obtained, additional increments of phenylephrine (10 mg or more) are added to the infusion bottle. The rate of flow is then adjusted until the desired blood pressure level is obtained. (In some cases, a more potent vasopressor, such as norepinephrine bitartrate, may be required.) Hypertension should be avoided. The blood pressure should be checked frequently. Headache and/or bradycardia may indicate hypertension. Arrhythmias are rare.

Spinal Anesthesia-Hypotension
Routine parenteral use of phenylephrine has been recommended for the prophylaxis and treatment of hypotension during spinal anesthesia. It is best administered subcutaneously or intramuscularly three or four minutes before injection of the spinal anesthetic. The total requirement for high anesthetic levels is usually 3 mg, and for lower levels, 2 mg. For hypotensive emergencies during spinal anesthesia, phenylephrine may be injected intravenously, using an initial dose of 0.2 mg. Any subsequent dose should not exceed the previous dose by more than 0.1 mg to 0.2 mg and no more than 0.5 mg should be administered in a single dose.

To combat hypotension during spinal anesthesia in children, a dose of 0.5 mg to 1 mg per 25 pounds body weight, administered subcutaneously or intramuscularly, is recommended.

Prolongation of Spinal Anesthesia
The addition of 2 mg to 5 mg of phenylephrine hydrochloride to the anesthetic solution increases the duration of motor block by as much as approximately 50 percent without any increase in the incidence of complications such as nausea, vomiting or blood pressure disturbances.

Vasoconstrictor for Regional Analgesia
Concentrations about ten times those employed when epinephrine is used as a vasoconstrictor are recommended. The optimum strength is 1:20,000 (made by adding 1 mg of phenylephrine hydrochloride to every 20 mL of local anesthetic solution). Some pressor responses can be expected when 2 mg or more are injected.

Paroxysmal Supraventricular Tachycardia
Rapid intravenous injection (within 20 to 30 seconds) is recommended. The initial dose should not exceed 0.5 mg, and subsequent doses, which are determined by the initial blood pressure response, should not exceed the preceding dose by more than 0.1 mg to 0.2 mg and should never exceed 1 mg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Source:
Product Information (current packaging): PHENYLEPHRINE HYDROCHLORIDE- phenylephrine hydrochloride injection. Baxter Healthcare Corporation, Deerfield, IL 60015; 2014.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
no_routine_adjustment_identified
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      phenylephrine
      Source IDH51-92C6360E9604EB6E8EAFB3F2
      Generic name
      Phenylephrine
      Source IDH51-4D08A93E4F4AAFCDD130FD59
      Class
      Cardiovascular and vasoactive
      Source IDH51-67DB5A4BD3EEF6B36BB7372C
      Subclass
      Alpha-1 agonist vasopressor
      Source IDH51-8730A829E90D362795642BCF
      Primary uses
      1. Vasodilatory hypotension
        Source IDH51-50745340FE3BD3CF170384EB
      2. Perioperative hypotension
        Source IDH51-9C1063CB120C7F95F46E6223
      Mechanism
      Selectively stimulates alpha-1 receptors and produces vasoconstriction.
      Source IDH51-2DEA828908340A7B75E77B45
      Mechanism level
      drug_specific
      Source IDH51-BEBF6668CE3679043AF82482
      Basic dosing orientation
      Adult infusion | Existing preparation record; use current package insert for indication-specific selection | Common bag 50 to 100 mg | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult perioperative or critical care | Common bolus 50 to 200 mcg under protocol | Common bolus 50 to 200 mcg under protocol | Patient- and indication-specific | See current package insert | IV push
      Source IDH51-A4A7C3665419A63EFF64D1EF
      Administration orientation
      Titrate by mcg/min; Administer as a controlled bolus with continuous hemodynamic monitoring; Standardized ready-to-administer concentration, often 100 mcg/mL; Administer as a controlled bolus with continuous hemodynamic monitoring
      Source IDH51-95768AF0AB9242241907E7C4
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-8C5597DDC82D406EAD5A7F4E
      Key safety orientation
      1. Concentrated stock-to-bolus errors can be fatal.
        Source IDH51-89F0D0A952132C21EFE09BB1
      2. Extravasation and peripheral ischemia.
        Source IDH51-A7296BB22726888543C3BC09
      3. May reduce cardiac output.
        Source IDH51-7127FB22F8587AD0ED44C4C3
      Coverage path
      structured_local_snapshot
      Source IDH51-A044C3ECD9968A4C71483C74
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-B5D2A543ECF1768C8764D267
      Legacy title
      Phenylephrine
      Source IDH51-FE84B4997672945023F1979E
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-E98F236239B70564E8CCE773
      Search text
      Phenylephrine Cardiovascular and vasoactive Alpha-1 agonist vasopressor Vasodilatory hypotension Perioperative hypotension Selectively stimulates alpha-1 receptors and produces vasoconstriction. Adult infusion | Existing preparation record; use current package insert for indication-specific selection | Common bag 50 to 100 mg | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult perioperative or critical care | Common bolus 50 to 200 mcg under protocol | Common bolus 50 to 200 mcg under protocol | Patient- and indication-specific | See current package insert | IV push Titrate by mcg/min; Administer as a controlled bolus with continuous hemodynamic monitoring; Standardized ready-to-administer concentration, often 100 mcg/mL; Administer as a controlled bolus with continuous hemodynamic monitoring No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context. Concentrated stock-to-bolus errors can be fatal. Extravasation and peripheral ischemia. May reduce cardiac output. Structured GlobalRPh route snapshot
      Source IDH51-693259C67361311463B1DF6E
      Official access mode
      search
      Source IDH51-4490ADD9F620B0CA711C8BC6
      Official search query
      Phenylephrine
      Source IDH51-E0D232E0E0CE86158817051F
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-38C9564812D7EF715EF7CC5A

      No separate structured rows were bundled for dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-6EE9F763540D6CD18691015B
      Adult infusion
      Source IDH51-475170A08624DEECF7DB6F17
      Common bag 50 to 100 mg
      Source IDH51-3074FC82BA8496AB428A4855
      Dilute concentrated vial or use premix.
      Source IDH51-D37D022BFDD0B3EC65CEE350
      NS or D5W
      Source IDH51-86D225E11613B4B7E127444B
      250 mL
      Source IDH51-DF44FDE229F5AF557C41EE5B
      200 to 400 mcg/mL commonly
      Source IDH51-7DE37173EF449FC9948632EC
      Titrate by mcg/min
      Source IDH51-8E063FDD1C3E0262EA4720B0
      Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-B7096A512CFA93E1910EEAAF
      Use institutional standard concentration and pump library.
      Source IDH51-2B6FFCEBC84EEFC49BFCC2FD

      Historical IV-push guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationDose scopeConcentrationRateStatusNotes
      Source IDH51-D236143282C90E429ADC86F3
      Adult perioperative or critical care
      Source IDH51-600C9F617A207EC9D3EFB5C1
      Common bolus 50 to 200 mcg under protocol
      Source IDH51-CEF73D6FA23BB323846B13E5
      Standardized ready-to-administer concentration, often 100 mcg/mL
      Source IDH51-259F9E3B12873200604E1164
      Administer as a controlled bolus with continuous hemodynamic monitoring
      Source IDH51-B845B21D36074E55088E6CFF
      Protocol-controlled only
      Source IDH51-657980109AAB1D20AAC994C3
      Never draw a bedside bolus directly from 10 mg/mL concentrate without pharmacy-standard dilution.
      Source IDH51-7C9A3CB3E6E21F8C3C47D63C

      Historical continuous-infusion guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationStandard concentrationInitial rateTitrationMaximumNotes
      Source IDH51-FE60C33AA03235FBF118C3F1
      Adult
      Source IDH51-40BA3D71115802A9029A2F6F
      50 mg/250 mL (200 mcg/mL) or 100 mg/250 mL (400 mcg/mL)
      Source IDH51-2DEF2BF24CCB120674F8491C
      Commonly 10 to 50 mcg/min
      Source IDH51-E12083082E35D352D1ECCBB2
      Titrate to blood pressure and perfusion target
      Source IDH51-4CC8B932F6AD9E713A1F68E6
      Protocol-specific
      Source IDH51-66D9BA1A187215C0FC26B44C
      Reflex bradycardia and reduced stroke volume may limit use.
      Source IDH51-A968E5C03196DC72494EB14A

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-91B258E54E66E09363B28CBC
      IV infusion
      Source IDH51-522717DE565A0A2C912CEF0C
      Adult infusion
      Source IDH51-02AA69FB7417BEBA2217A9F2
      Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-A91ABE60B8A938FD303EB09B
      Common bag 50 to 100 mg
      Source IDH51-52B1AF0C9547C38719C36407
      Not normalized in the preparation record
      Source IDH51-2F210E10CEA15D34B153D2F1
      See current package insert and professional guidance
      Source IDH51-3EA31E43F92FB1412609DF0C
      Titrate by mcg/min
      Source IDH51-815A20F14064B2F36E6EEDCA
      Existing GlobalRPh structured preparation snapshot
      Source IDH51-528D63C17D37999799526945
      Use institutional standard concentration and pump library.
      Source IDH51-60C3A0C55B24FC11AE9CC67C
      Source IDH51-57FB039B32C635FA1BB74C53
      IV push
      Source IDH51-AAFD233CD642EF8A2BE9563D
      Adult perioperative or critical care
      Source IDH51-DC16B761B66089EDC25BF94C
      Common bolus 50 to 200 mcg under protocol
      Source IDH51-5E1511AE436C3A2AF4915D2D
      Common bolus 50 to 200 mcg under protocol
      Source IDH51-6920CFEE660D20E0675444B4
      Patient- and indication-specific
      Source IDH51-07DC690973835CC35DDEB385
      See current package insert
      Source IDH51-481E3B3870D035617E26BDB0
      Administer as a controlled bolus with continuous hemodynamic monitoring
      Source IDH51-0A5693ACD6EFC8A43C21C223
      Existing GlobalRPh IV push snapshot
      Source IDH51-56D3CA4C2D760A1EC174CAE2
      Protocol-controlled only Never draw a bedside bolus directly from 10 mg/mL concentrate without pharmacy-standard dilution.
      Source IDH51-CA5E39F0F49A01EF601165C4
      Source IDH51-62701F4666D5B7C090CC4133
      Continuous IV infusion
      Source IDH51-2F0B857975795D9B8558D8FE
      Adult
      Source IDH51-635C3CE288D356B3A59B9B5A
      Existing continuous-infusion record
      Source IDH51-C79850B054D30E2D8686AB26
      Commonly 10 to 50 mcg/min
      Source IDH51-CD76DB9652D60B7D3922C5DA
      Continuous infusion; titration-specific
      Source IDH51-5F116D3EC366BA342F9AE034
      Clinical-response dependent
      Source IDH51-AFEC28ABB7B81DAECB146751
      Titrate to blood pressure and perfusion target
      Source IDH51-635AAB1217E74F125FBC45F1
      Existing GlobalRPh continuous-infusion snapshot
      Source IDH51-204D97D1AB79E335FDCD82A7
      Protocol-specific Reflex bradycardia and reduced stroke volume may limit use.
      Source IDH51-2E41C1D333A0629D36B4507B

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      no_routine_adjustment_identified
      Source IDH51-01A01ACEAA59DFF9F25FA15F
      Summary
      No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-569170731FE42E4BE2718699
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-75C9DC886CD8F98CD4F6594C

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Vasodilatory hypotension
        Source IDH51-1A5CEEFB1A2D056323CC948E
      2. Perioperative hypotension
        Source IDH51-75253AAD2F64F80632357D82

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Concentrated stock-to-bolus errors can be fatal.
        Source IDH51-0F6951811B338526100967FA
      2. Extravasation and peripheral ischemia.
        Source IDH51-9908B4B62B4A41270AD5A489
      3. May reduce cardiac output.
        Source IDH51-D1FAE08A970DAAE4792B8FD1

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      1. Continuous blood pressure
        Source IDH51-8F38F000E08DD39C82C61335
      2. Heart rate and rhythm
        Source IDH51-8366B6DDB8B9A49726350938
      3. Peripheral perfusion and IV site
        Source IDH51-A9CEAA9BFFAD8C913202B9F1
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      phenylephrine
      Source IDH51-4AAF0CF54E6E48545A67EFD6
      Generic name
      Phenylephrine
      Source IDH51-FB2286255BEC6C07591BDCE3
      Brand names
      1. Neo-Synephrine
        Source IDH51-9F424F68D33585701566A593
      Class
      Cardiovascular and vasoactive
      Source IDH51-F368B840C48AB89F21A65370
      Subclass
      Alpha-1 agonist vasopressor
      Source IDH51-A5835AB0176229F792E19E88
      Summary
      Pure alpha-agonist used as a titrated infusion or carefully standardized bolus; concentrated stock must never be confused with bedside bolus concentration.
      Source IDH51-C33ACFB5D91C0A1178D29986
      Populations
      1. Adult
        Source IDH51-238319318F3FD9BB52824FED
      Evidence tier
      Core reference - verify current label
      Source IDH51-80DE1E880AD6E2D8104CEDD0
      High alert
      true
      Source IDH51-CE1A5A70A5EC85A673A182D5
      Hazardous
      false
      Source IDH51-766A82AEAB2B19EFC48BB3F6
      Status
      Active
      Source IDH51-D4F94724BCF43FCB6ECE528D
      Reviewed
      2026-08-29
      Source IDH51-8BF48353814616E2330267E5
      Version added
      1.0
      Source IDH51-14E9B269806390850636424A
      Sources
      LabelUrlKind
      Source IDH51-52D06A8B058AAF4F23926B5E
      DailyMed label search
      Source IDH51-006CCB0EE8C7ABC27F651BA4
      https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Phenylephrine (opens in a new tab)
      Source IDH51-12EE131017BEC9A5C5CB462D
      Primary
      Source IDH51-9C3D1B633B228B5A47DC7397
      Source IDH51-79A96081E83F9CA7AA9314A1
      GlobalRPh legacy IV dilution monograph
      Source IDH51-4527187D692395BCF146CFA4
      legacy:auto
      Source IDH51-5546F145216302060B8EFA51
      Legacy
      Source IDH51-028E0A1B3A6BF32BFC6496AB
      Legacy title
      Phenylephrine
      Source IDH51-E41FC45CB92BB319132A4624
      Clinical release verification
      Audit version
      3.4
      Source IDH51-34C35B5A08EB4F083087E560
      Audited on
      2026-08-30
      Source IDH51-62142F7CC8A3246F5178895A
      Level
      amber
      Source IDH51-C551FF65E894639D2B873F76
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-C834A96EAE4B15D36024F2D7
      Exact current label candidate
      false
      Source IDH51-149790E225E164165447F381
      Numeric support ratio
      0
      Source IDH51-FF666463A60A769240E2C21F
      Reference url count
      1
      Source IDH51-FEE051B38D4DBD34A5820220
      Broken reference count
      0
      Source IDH51-2B04C3A8107E5CD44DC062DE
      Point of use confirmation required
      true
      Source IDH51-92E4AECDBC5564355FBC0A41
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-D45A23C950F0C0AF07CAF5F6

      Dosing source fields

      Id
      phenylephrine
      Source IDH51-5ACBF7A0BA1EB50292BF64C4
      Generic name
      Phenylephrine
      Source IDH51-727989CB9E442ECBB8861931
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-67D124677671C90CC346565F
      Package insert
      Query name
      Phenylephrine
      Source IDH51-D8471A9733A7A93DA052A5CB
      Product and route must match
      true
      Source IDH51-EBF9792742087CA7710DCA98
      Live current label enabled
      false
      Source IDH51-18CF5AB2766EB631266ED668
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-A7B1F6D3097751B2E622B553
      Direct official label access enabled
      true
      Source IDH51-3307B5F334B1AA4E7E138EA6
      Outbound server request required
      false
      Source IDH51-03EABF234D2330059C40EC1B
      Local summary status
      not_bundled
      Source IDH51-8A95CFE6CB3F4AD95E57E086
      Clinical review
      Locally normalized
      false
      Source IDH51-52C4AA4BCF93B40CF7F0595A
      Reviewed
      2026-08-29
      Source IDH51-C2CB72BBCAB111597723B2C3
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-B3A63176A91BEA272BA6E157
      Clinical release verification
      Audit version
      3.4
      Source IDH51-815A84A357F1B7E65FEFACD7
      Audited on
      2026-08-30
      Source IDH51-F570BAF024448ED4A4444E86
      Level
      amber
      Source IDH51-1C3B429B512918BB48729A4D
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-8946EE09B057A01FF9B77F67
      Exact current label candidate
      false
      Source IDH51-4B3155181A60BD232733D33E
      Numeric support ratio
      0
      Source IDH51-3995BA8BF8304C633A814C07
      Reference url count
      1
      Source IDH51-5E58F23165636B243E84E368
      Broken reference count
      0
      Source IDH51-A351C5D710D5885222CF5ED1
      Point of use confirmation required
      true
      Source IDH51-22C554F2AB349E6C5FB251E7
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-388B2AE2C0C15DEA56377B2D
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      phenylephrine
      Source IDH51-7E11D18504903ED51E1FA0B4
      Name
      Phenylephrine
      Source IDH51-8AA0C4D27E681C107F7633CA
      Brands
      Neo-Synephrine
      Source IDH51-FB4BDBFD06E8780A4D818262
      Therapeutic class
      Cardiovascular and vasoactive
      Source IDH51-E8B358A10189BF28B254A19E
      Review version
      3.1
      Source IDH51-7FC2CE7FF2688A535B36F582
      Review date
      2026-08-30
      Source IDH51-C874DE30702052B74D9E8145
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-69996E751FF5F29D72F38B3B
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-613CFB4B8C749D583BF18E35
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-BFEE642BF3662E64E4C3672C
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-904882CE2F3D43E13E91F9AF
      Reconstitution concentration
      Dilute concentrated vial or use premix.
      Source IDH51-B56A4A800187EE05A7B1358C
      Maximum or recommended final concentration
      50 mg/250 mL (200 mcg/mL) or 100 mg/250 mL (400 mcg/mL)
      Source IDH51-65256CB863E6C71ECE08DE12
      Appropriate standardized containers
      250 mL
      Source IDH51-31D7114CA73D201D8648CDC9
      Adult dosing range
      Common bag 50 to 100 mg Common bolus 50 to 200 mcg under protocol Commonly 10 to 50 mcg/min Common bolus 50 to 200 mcg under protocol
      Source IDH51-566430559C80850E2774BDB2
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D74314B87C71B82F39B6D241
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E02831975589FBDA05753965
      Infusion time
      Titrate by mcg/min Administer as a controlled bolus with continuous hemodynamic monitoring Commonly 10 to 50 mcg/min
      Source IDH51-6A053A6D57947D02EF4945E8
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-A66DCB88DF8181355FE1F7D0
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-11F57F689C79C9EE098E308C
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-FE83F8278D635FC731ECD48D
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-5FBEE81FC2FE3053BE3D1400
      Maximum or recommended final concentration
      Primary
      existing_structured_record
      Source IDH51-845A21E2596DFA14D3230B18
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-F9579D91A33B765D2865A407
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-13C25ED36112501A6F7EAD6A
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-AE794510CB05FD6301A17259
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-C01318EEBD5CF2CEF5DB6661
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-1086A9BA74DE093D362E77EE
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-5CB2D71BBA91AE57975F2E84
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-185A0985580872C3A80D4774
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-1B02D8C5CFFB6959C1C20233
      Guide generation allowed
      true
      Source IDH51-15895E679E05E83BEBEB9472
      Pediatric
      Applicability
      not_established
      Source IDH51-9EDCD4048BDF7144A9589AD1
      Guide generation allowed
      false
      Source IDH51-24E9C8ABDEA0A2506AB6946D
      Neonatal
      Applicability
      not_established
      Source IDH51-A4B9D735D9DC5218F3B88619
      Guide generation allowed
      false
      Source IDH51-28C11D6A6DD33AAC748F823F
      Route presence
      Structured dilution
      true
      Source IDH51-863923360F244D8F4DE800D6
      Iv push
      true
      Source IDH51-EF288967521394A224B7C23C
      Continuous infusion
      true
      Source IDH51-2753A45D8E57E32012B247E0
      Pediatric source
      false
      Source IDH51-B6E50094AAE503E7FEDD7185
      Neonatal source
      false
      Source IDH51-BE8632BD23E46AA917BC9F10
      Legacy reference
      Status
      not_available
      Source IDH51-CDF0DD5124D2E382B096081E
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-31BE38B40D9297A3120726EF
      Concentration values detected
      HighUnitText
      Source IDH51-8319BA42A5E4BEFB9EE02231
      200
      Source IDH51-ED6204653BF3D1064FAAAF37
      mcg
      Source IDH51-86D71E82085561FAFA06E518
      200 mcg/mL
      Source IDH51-81ED97F04A17D58F00B61AAD
      Source IDH51-157A9AA31ED8B4DD6AD8789B
      400
      Source IDH51-588A576EBD5D964F60A5CAD4
      mcg
      Source IDH51-3FDDB217BAEB3F00CC8B3826
      400 mcg/mL
      Source IDH51-A4E2046FE87F1CAEC7BF357D
      Source files
      1. catalog.json
        Source IDH51-7B9C6432AC9ED72EDDA59D2F
      2. dosing.json
        Source IDH51-EEFB0C3660A2B7FDF414F9FB
      3. legacy-map.json
        Source IDH51-C2E1D91E737A95B150CDD27B
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-6CE31E94CF874778864BE0BF
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-4AAF0CF54E6E48545A67EFD6catalog.json
      /records/196/id
      Historical; current review incomplete
      H51-FB2286255BEC6C07591BDCE3catalog.json
      /records/196/generic_name
      Historical; current review incomplete
      H51-9F424F68D33585701566A593catalog.json
      /records/196/brand_names/0
      Historical; current review incomplete
      H51-F368B840C48AB89F21A65370catalog.json
      /records/196/class
      Historical; current review incomplete
      H51-A5835AB0176229F792E19E88catalog.json
      /records/196/subclass
      Historical; current review incomplete
      H51-C33ACFB5D91C0A1178D29986catalog.json
      /records/196/summary
      Historical; current review incomplete
      H51-1A5CEEFB1A2D056323CC948Ecatalog.json
      /records/196/common_uses/0
      Historical; current review incomplete
      H51-75253AAD2F64F80632357D82catalog.json
      /records/196/common_uses/1
      Historical; current review incomplete
      H51-6EE9F763540D6CD18691015Bcatalog.json
      /records/196/preparations/0
      Historical; current review incomplete
      H51-475170A08624DEECF7DB6F17catalog.json
      /records/196/preparations/0/population
      Historical; current review incomplete
      H51-3074FC82BA8496AB428A4855catalog.json
      /records/196/preparations/0/amount
      Historical; current review incomplete
      H51-D37D022BFDD0B3EC65CEE350catalog.json
      /records/196/preparations/0/reconstitution
      Historical; current review incomplete
      H51-86D225E11613B4B7E127444Bcatalog.json
      /records/196/preparations/0/diluent
      Historical; current review incomplete
      H51-DF44FDE229F5AF557C41EE5Bcatalog.json
      /records/196/preparations/0/final_volume
      Historical; current review incomplete
      H51-7DE37173EF449FC9948632ECcatalog.json
      /records/196/preparations/0/concentration
      Historical; current review incomplete
      H51-8E063FDD1C3E0262EA4720B0catalog.json
      /records/196/preparations/0/rate
      Historical; current review incomplete
      H51-B7096A512CFA93E1910EEAAFcatalog.json
      /records/196/preparations/0/stability
      Historical; current review incomplete
      H51-2B6FFCEBC84EEFC49BFCC2FDcatalog.json
      /records/196/preparations/0/notes
      Historical; current review incomplete
      H51-D236143282C90E429ADC86F3catalog.json
      /records/196/iv_push/0
      Historical; current review incomplete
      H51-600C9F617A207EC9D3EFB5C1catalog.json
      /records/196/iv_push/0/population
      Historical; current review incomplete
      H51-CEF73D6FA23BB323846B13E5catalog.json
      /records/196/iv_push/0/dose_scope
      Historical; current review incomplete
      H51-259F9E3B12873200604E1164catalog.json
      /records/196/iv_push/0/concentration
      Historical; current review incomplete
      H51-B845B21D36074E55088E6CFFcatalog.json
      /records/196/iv_push/0/rate
      Historical; current review incomplete
      H51-657980109AAB1D20AAC994C3catalog.json
      /records/196/iv_push/0/status
      Historical; current review incomplete
      H51-7C9A3CB3E6E21F8C3C47D63Ccatalog.json
      /records/196/iv_push/0/notes
      Historical; current review incomplete
      H51-FE60C33AA03235FBF118C3F1catalog.json
      /records/196/continuous_infusions/0
      Historical; current review incomplete
      H51-40BA3D71115802A9029A2F6Fcatalog.json
      /records/196/continuous_infusions/0/population
      Historical; current review incomplete
      H51-2DEF2BF24CCB120674F8491Ccatalog.json
      /records/196/continuous_infusions/0/standard_concentration
      Historical; current review incomplete
      H51-E12083082E35D352D1ECCBB2catalog.json
      /records/196/continuous_infusions/0/initial_rate
      Historical; current review incomplete
      H51-4CC8B932F6AD9E713A1F68E6catalog.json
      /records/196/continuous_infusions/0/titration
      Historical; current review incomplete
      H51-66D9BA1A187215C0FC26B44Ccatalog.json
      /records/196/continuous_infusions/0/maximum
      Historical; current review incomplete
      H51-A968E5C03196DC72494EB14Acatalog.json
      /records/196/continuous_infusions/0/notes
      Historical; current review incomplete
      H51-0F6951811B338526100967FAcatalog.json
      /records/196/warnings/0
      Historical; current review incomplete
      H51-9908B4B62B4A41270AD5A489catalog.json
      /records/196/warnings/1
      Historical; current review incomplete
      H51-D1FAE08A970DAAE4792B8FD1catalog.json
      /records/196/warnings/2
      Historical; current review incomplete
      H51-8F38F000E08DD39C82C61335catalog.json
      /records/196/monitoring/0
      Historical; current review incomplete
      H51-8366B6DDB8B9A49726350938catalog.json
      /records/196/monitoring/1
      Historical; current review incomplete
      H51-A9CEAA9BFFAD8C913202B9F1catalog.json
      /records/196/monitoring/2
      Historical; current review incomplete
      H51-238319318F3FD9BB52824FEDcatalog.json
      /records/196/populations/0
      Historical; current review incomplete
      H51-80DE1E880AD6E2D8104CEDD0catalog.json
      /records/196/evidence_tier
      Historical; current review incomplete
      H51-CE1A5A70A5EC85A673A182D5catalog.json
      /records/196/high_alert
      Historical; current review incomplete
      H51-766A82AEAB2B19EFC48BB3F6catalog.json
      /records/196/hazardous
      Historical; current review incomplete
      H51-D4F94724BCF43FCB6ECE528Dcatalog.json
      /records/196/status
      Historical; current review incomplete
      H51-8BF48353814616E2330267E5catalog.json
      /records/196/reviewed
      Historical; current review incomplete
      H51-14E9B269806390850636424Acatalog.json
      /records/196/version_added
      Historical; current review incomplete
      H51-52D06A8B058AAF4F23926B5Ecatalog.json
      /records/196/sources/0
      Historical; current review incomplete
      H51-006CCB0EE8C7ABC27F651BA4catalog.json
      /records/196/sources/0/label
      Historical; current review incomplete
      H51-12EE131017BEC9A5C5CB462Dcatalog.json
      /records/196/sources/0/url
      Historical; current review incomplete
      H51-9C3D1B633B228B5A47DC7397catalog.json
      /records/196/sources/0/kind
      Historical; current review incomplete
      H51-79A96081E83F9CA7AA9314A1catalog.json
      /records/196/sources/1
      Historical; current review incomplete
      H51-4527187D692395BCF146CFA4catalog.json
      /records/196/sources/1/label
      Historical; current review incomplete
      H51-5546F145216302060B8EFA51catalog.json
      /records/196/sources/1/url
      Historical; current review incomplete
      H51-028E0A1B3A6BF32BFC6496ABcatalog.json
      /records/196/sources/1/kind
      Historical; current review incomplete
      H51-E41FC45CB92BB319132A4624catalog.json
      /records/196/legacy_title
      Historical; current review incomplete
      H51-34C35B5A08EB4F083087E560catalog.json
      /records/196/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-62142F7CC8A3246F5178895Acatalog.json
      /records/196/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-C551FF65E894639D2B873F76catalog.json
      /records/196/clinical_release_verification/level
      Historical; current review incomplete
      H51-C834A96EAE4B15D36024F2D7catalog.json
      /records/196/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-149790E225E164165447F381catalog.json
      /records/196/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-42F0D59CC6E24D4B2DE82A12catalog.json
      /records/196/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-3A4CADD55D595FEEC664731Ecatalog.json
      /records/196/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-FF666463A60A769240E2C21Fcatalog.json
      /records/196/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-FEE051B38D4DBD34A5820220catalog.json
      /records/196/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-2B04C3A8107E5CD44DC062DEcatalog.json
      /records/196/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-92E4AECDBC5564355FBC0A41catalog.json
      /records/196/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-D45A23C950F0C0AF07CAF5F6catalog.json
      /records/196/clinical_release_verification/note
      Historical; current review incomplete
      H51-9807959DA9CD447849C0FB16catalog.json
      /records/196/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-5ACBF7A0BA1EB50292BF64C4dosing.json
      /records/196/id
      Historical; current review incomplete
      H51-727989CB9E442ECBB8861931dosing.json
      /records/196/generic_name
      Historical; current review incomplete
      H51-67D124677671C90CC346565Fdosing.json
      /records/196/coverage_status
      Historical; current review incomplete
      H51-D8471A9733A7A93DA052A5CBdosing.json
      /records/196/package_insert/query_name
      Historical; current review incomplete
      H51-BBF2C8D770A3E91DDF05F92Ddosing.json
      /records/196/package_insert/preferred_setid
      Historical; current review incomplete
      H51-EBF9792742087CA7710DCA98dosing.json
      /records/196/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-18CF5AB2766EB631266ED668dosing.json
      /records/196/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-A7B1F6D3097751B2E622B553dosing.json
      /records/196/package_insert/source_priority
      Historical; current review incomplete
      H51-3307B5F334B1AA4E7E138EA6dosing.json
      /records/196/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-03EABF234D2330059C40EC1Bdosing.json
      /records/196/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-8A95CFE6CB3F4AD95E57E086dosing.json
      /records/196/package_insert/local_summary_status
      Historical; current review incomplete
      H51-01A01ACEAA59DFF9F25FA15Fdosing.json
      /records/196/renal/classification
      Historical; current review incomplete
      H51-569170731FE42E4BE2718699dosing.json
      /records/196/renal/summary
      Historical; current review incomplete
      H51-75C9DC886CD8F98CD4F6594Cdosing.json
      /records/196/renal/method_note
      Historical; current review incomplete
      H51-91B258E54E66E09363B28CBCdosing.json
      /records/196/existing_route_snapshots/0
      Historical; current review incomplete
      H51-522717DE565A0A2C912CEF0Cdosing.json
      /records/196/existing_route_snapshots/0/route
      Historical; current review incomplete
      H51-02AA69FB7417BEBA2217A9F2dosing.json
      /records/196/existing_route_snapshots/0/population
      Historical; current review incomplete
      H51-A91ABE60B8A938FD303EB09Bdosing.json
      /records/196/existing_route_snapshots/0/indication
      Historical; current review incomplete
      H51-52B1AF0C9547C38719C36407dosing.json
      /records/196/existing_route_snapshots/0/dose
      Historical; current review incomplete
      H51-2F210E10CEA15D34B153D2F1dosing.json
      /records/196/existing_route_snapshots/0/interval
      Historical; current review incomplete
      H51-3EA31E43F92FB1412609DF0Cdosing.json
      /records/196/existing_route_snapshots/0/duration
      Historical; current review incomplete
      H51-815A20F14064B2F36E6EEDCAdosing.json
      /records/196/existing_route_snapshots/0/administration
      Historical; current review incomplete
      H51-528D63C17D37999799526945dosing.json
      /records/196/existing_route_snapshots/0/source_level
      Historical; current review incomplete
      H51-60C3A0C55B24FC11AE9CC67Cdosing.json
      /records/196/existing_route_snapshots/0/notes
      Historical; current review incomplete
      H51-57FB039B32C635FA1BB74C53dosing.json
      /records/196/existing_route_snapshots/1
      Historical; current review incomplete
      H51-AAFD233CD642EF8A2BE9563Ddosing.json
      /records/196/existing_route_snapshots/1/route
      Historical; current review incomplete
      H51-DC16B761B66089EDC25BF94Cdosing.json
      /records/196/existing_route_snapshots/1/population
      Historical; current review incomplete
      H51-5E1511AE436C3A2AF4915D2Ddosing.json
      /records/196/existing_route_snapshots/1/indication
      Historical; current review incomplete
      H51-6920CFEE660D20E0675444B4dosing.json
      /records/196/existing_route_snapshots/1/dose
      Historical; current review incomplete
      H51-07DC690973835CC35DDEB385dosing.json
      /records/196/existing_route_snapshots/1/interval
      Historical; current review incomplete
      H51-481E3B3870D035617E26BDB0dosing.json
      /records/196/existing_route_snapshots/1/duration
      Historical; current review incomplete
      H51-0A5693ACD6EFC8A43C21C223dosing.json
      /records/196/existing_route_snapshots/1/administration
      Historical; current review incomplete
      H51-56D3CA4C2D760A1EC174CAE2dosing.json
      /records/196/existing_route_snapshots/1/source_level
      Historical; current review incomplete
      H51-CA5E39F0F49A01EF601165C4dosing.json
      /records/196/existing_route_snapshots/1/notes
      Historical; current review incomplete
      H51-62701F4666D5B7C090CC4133dosing.json
      /records/196/existing_route_snapshots/2
      Historical; current review incomplete
      H51-2F0B857975795D9B8558D8FEdosing.json
      /records/196/existing_route_snapshots/2/route
      Historical; current review incomplete
      H51-635C3CE288D356B3A59B9B5Adosing.json
      /records/196/existing_route_snapshots/2/population
      Historical; current review incomplete
      H51-C79850B054D30E2D8686AB26dosing.json
      /records/196/existing_route_snapshots/2/indication
      Historical; current review incomplete
      H51-CD76DB9652D60B7D3922C5DAdosing.json
      /records/196/existing_route_snapshots/2/dose
      Historical; current review incomplete
      H51-5F116D3EC366BA342F9AE034dosing.json
      /records/196/existing_route_snapshots/2/interval
      Historical; current review incomplete
      H51-AFEC28ABB7B81DAECB146751dosing.json
      /records/196/existing_route_snapshots/2/duration
      Historical; current review incomplete
      H51-635AAB1217E74F125FBC45F1dosing.json
      /records/196/existing_route_snapshots/2/administration
      Historical; current review incomplete
      H51-204D97D1AB79E335FDCD82A7dosing.json
      /records/196/existing_route_snapshots/2/source_level
      Historical; current review incomplete
      H51-2E41C1D333A0629D36B4507Bdosing.json
      /records/196/existing_route_snapshots/2/notes
      Historical; current review incomplete
      H51-52C4AA4BCF93B40CF7F0595Adosing.json
      /records/196/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-C2CB72BBCAB111597723B2C3dosing.json
      /records/196/clinical_review/reviewed
      Historical; current review incomplete
      H51-B3A63176A91BEA272BA6E157dosing.json
      /records/196/clinical_review/status
      Historical; current review incomplete
      H51-815A84A357F1B7E65FEFACD7dosing.json
      /records/196/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-F570BAF024448ED4A4444E86dosing.json
      /records/196/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-1C3B429B512918BB48729A4Ddosing.json
      /records/196/clinical_release_verification/level
      Historical; current review incomplete
      H51-8946EE09B057A01FF9B77F67dosing.json
      /records/196/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-4B3155181A60BD232733D33Edosing.json
      /records/196/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-E26C0EED7D03D653A24109ACdosing.json
      /records/196/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-5CE09CFB6725074962D1F0A2dosing.json
      /records/196/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-3995BA8BF8304C633A814C07dosing.json
      /records/196/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-5E58F23165636B243E84E368dosing.json
      /records/196/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-A351C5D710D5885222CF5ED1dosing.json
      /records/196/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-22C554F2AB349E6C5FB251E7dosing.json
      /records/196/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-388B2AE2C0C15DEA56377B2Ddosing.json
      /records/196/clinical_release_verification/note
      Historical; current review incomplete
      H51-7CC69D9AA1EDDA5A60F8B294dosing.json
      /records/196/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-92C6360E9604EB6E8EAFB3F2first-look-v5.1.json
      /records/196/id
      Historical; current review incomplete
      H51-4D08A93E4F4AAFCDD130FD59first-look-v5.1.json
      /records/196/generic_name
      Historical; current review incomplete
      H51-67DB5A4BD3EEF6B36BB7372Cfirst-look-v5.1.json
      /records/196/class
      Historical; current review incomplete
      H51-8730A829E90D362795642BCFfirst-look-v5.1.json
      /records/196/subclass
      Historical; current review incomplete
      H51-50745340FE3BD3CF170384EBfirst-look-v5.1.json
      /records/196/primary_uses/0
      Historical; current review incomplete
      H51-9C1063CB120C7F95F46E6223first-look-v5.1.json
      /records/196/primary_uses/1
      Historical; current review incomplete
      H51-2DEA828908340A7B75E77B45first-look-v5.1.json
      /records/196/mechanism
      Historical; current review incomplete
      H51-BEBF6668CE3679043AF82482first-look-v5.1.json
      /records/196/mechanism_level
      Historical; current review incomplete
      H51-A4A7C3665419A63EFF64D1EFfirst-look-v5.1.json
      /records/196/basic_dosing_orientation
      Historical; current review incomplete
      H51-95768AF0AB9242241907E7C4first-look-v5.1.json
      /records/196/administration_orientation
      Historical; current review incomplete
      H51-8C5597DDC82D406EAD5A7F4Efirst-look-v5.1.json
      /records/196/renal_and_population_orientation
      Historical; current review incomplete
      H51-89F0D0A952132C21EFE09BB1first-look-v5.1.json
      /records/196/key_safety_orientation/0
      Historical; current review incomplete
      H51-A7296BB22726888543C3BC09first-look-v5.1.json
      /records/196/key_safety_orientation/1
      Historical; current review incomplete
      H51-7127FB22F8587AD0ED44C4C3first-look-v5.1.json
      /records/196/key_safety_orientation/2
      Historical; current review incomplete
      H51-A044C3ECD9968A4C71483C74first-look-v5.1.json
      /records/196/coverage_path
      Historical; current review incomplete
      H51-B5D2A543ECF1768C8764D267first-look-v5.1.json
      /records/196/coverage_path_label
      Historical; current review incomplete
      H51-A57697121889C7AD79CD55D0first-look-v5.1.json
      /records/196/official_label_url
      Historical; current review incomplete
      H51-FE84B4997672945023F1979Efirst-look-v5.1.json
      /records/196/legacy_title
      Historical; current review incomplete
      H51-E98F236239B70564E8CCE773first-look-v5.1.json
      /records/196/review_note
      Historical; current review incomplete
      H51-693259C67361311463B1DF6Efirst-look-v5.1.json
      /records/196/search_text
      Historical; current review incomplete
      H51-06511DF3AD16484A5E8F3DF4first-look-v5.1.json
      /records/196/official_search_url
      Historical; current review incomplete
      H51-4490ADD9F620B0CA711C8BC6first-look-v5.1.json
      /records/196/official_access_mode
      Historical; current review incomplete
      H51-FB1CA713F70E73428377D106first-look-v5.1.json
      /records/196/official_access_url
      Historical; current review incomplete
      H51-E0D232E0E0CE86158817051Ffirst-look-v5.1.json
      /records/196/official_search_query
      Historical; current review incomplete
      H51-38C9564812D7EF715EF7CC5Afirst-look-v5.1.json
      /records/196/official_access_reason
      Historical; current review incomplete
      H51-7E11D18504903ED51E1FA0B4preparation-assessments-v3.8.json
      /196/id
      Historical; current review incomplete
      H51-8AA0C4D27E681C107F7633CApreparation-assessments-v3.8.json
      /196/name
      Historical; current review incomplete
      H51-FB4BDBFD06E8780A4D818262preparation-assessments-v3.8.json
      /196/brands
      Historical; current review incomplete
      H51-E8B358A10189BF28B254A19Epreparation-assessments-v3.8.json
      /196/therapeutic_class
      Historical; current review incomplete
      H51-7FC2CE7FF2688A535B36F582preparation-assessments-v3.8.json
      /196/review_version
      Historical; current review incomplete
      H51-C874DE30702052B74D9E8145preparation-assessments-v3.8.json
      /196/review_date
      Historical; current review incomplete
      H51-69996E751FF5F29D72F38B3Bpreparation-assessments-v3.8.json
      /196/release_status
      Historical; current review incomplete
      H51-613CFB4B8C749D583BF18E35preparation-assessments-v3.8.json
      /196/market_status/status
      Historical; current review incomplete
      H51-BFEE642BF3662E64E4C3672Cpreparation-assessments-v3.8.json
      /196/market_status/basis
      Historical; current review incomplete
      H51-904882CE2F3D43E13E91F9AFpreparation-assessments-v3.8.json
      /196/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-B56A4A800187EE05A7B1358Cpreparation-assessments-v3.8.json
      /196/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-65256CB863E6C71ECE08DE12preparation-assessments-v3.8.json
      /196/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-31D7114CA73D201D8648CDC9preparation-assessments-v3.8.json
      /196/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-566430559C80850E2774BDB2preparation-assessments-v3.8.json
      /196/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-D74314B87C71B82F39B6D241preparation-assessments-v3.8.json
      /196/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-E02831975589FBDA05753965preparation-assessments-v3.8.json
      /196/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-6A053A6D57947D02EF4945E8preparation-assessments-v3.8.json
      /196/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-A66DCB88DF8181355FE1F7D0preparation-assessments-v3.8.json
      /196/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-CAC8AC17D84C59DD608562C0preparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-51BBE75A8CA3D5E4900449C1preparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-CCA0BEAF9D7CD92DEF4351FApreparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-1016493F5E0A9752F031CBF2preparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-11F57F689C79C9EE098E308Cpreparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-C9102A917B671B68E8E423ACpreparation-assessments-v3.8.json
      /196/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-FE83F8278D635FC731ECD48Dpreparation-assessments-v3.8.json
      /196/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-5FBEE81FC2FE3053BE3D1400preparation-assessments-v3.8.json
      /196/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-845A21E2596DFA14D3230B18preparation-assessments-v3.8.json
      /196/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-F9579D91A33B765D2865A407preparation-assessments-v3.8.json
      /196/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-13C25ED36112501A6F7EAD6Apreparation-assessments-v3.8.json
      /196/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-AE794510CB05FD6301A17259preparation-assessments-v3.8.json
      /196/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-C01318EEBD5CF2CEF5DB6661preparation-assessments-v3.8.json
      /196/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-1086A9BA74DE093D362E77EEpreparation-assessments-v3.8.json
      /196/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-5CB2D71BBA91AE57975F2E84preparation-assessments-v3.8.json
      /196/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-185A0985580872C3A80D4774preparation-assessments-v3.8.json
      /196/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-1B02D8C5CFFB6959C1C20233preparation-assessments-v3.8.json
      /196/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-15895E679E05E83BEBEB9472preparation-assessments-v3.8.json
      /196/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-9EDCD4048BDF7144A9589AD1preparation-assessments-v3.8.json
      /196/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-24E9C8ABDEA0A2506AB6946Dpreparation-assessments-v3.8.json
      /196/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-A4B9D735D9DC5218F3B88619preparation-assessments-v3.8.json
      /196/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-28C11D6A6DD33AAC748F823Fpreparation-assessments-v3.8.json
      /196/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-863923360F244D8F4DE800D6preparation-assessments-v3.8.json
      /196/route_presence/structured_dilution
      Historical; current review incomplete
      H51-EF288967521394A224B7C23Cpreparation-assessments-v3.8.json
      /196/route_presence/iv_push
      Historical; current review incomplete
      H51-2753A45D8E57E32012B247E0preparation-assessments-v3.8.json
      /196/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-B6E50094AAE503E7FEDD7185preparation-assessments-v3.8.json
      /196/route_presence/pediatric_source
      Historical; current review incomplete
      H51-BE8632BD23E46AA917BC9F10preparation-assessments-v3.8.json
      /196/route_presence/neonatal_source
      Historical; current review incomplete
      H51-CDF0DD5124D2E382B096081Epreparation-assessments-v3.8.json
      /196/legacy_reference/status
      Historical; current review incomplete
      H51-31BE38B40D9297A3120726EFpreparation-assessments-v3.8.json
      /196/label_resolution/status
      Historical; current review incomplete
      H51-8319BA42A5E4BEFB9EE02231preparation-assessments-v3.8.json
      /196/concentration_values_detected/0
      Historical; current review incomplete
      H51-185AC32E4DE5FEB8405DB020preparation-assessments-v3.8.json
      /196/concentration_values_detected/0/low
      Historical; current review incomplete
      H51-ED6204653BF3D1064FAAAF37preparation-assessments-v3.8.json
      /196/concentration_values_detected/0/high
      Historical; current review incomplete
      H51-86D71E82085561FAFA06E518preparation-assessments-v3.8.json
      /196/concentration_values_detected/0/unit
      Historical; current review incomplete
      H51-81ED97F04A17D58F00B61AADpreparation-assessments-v3.8.json
      /196/concentration_values_detected/0/text
      Historical; current review incomplete
      H51-157A9AA31ED8B4DD6AD8789Bpreparation-assessments-v3.8.json
      /196/concentration_values_detected/1
      Historical; current review incomplete
      H51-A13FBB29626036E5A80C5CE6preparation-assessments-v3.8.json
      /196/concentration_values_detected/1/low
      Historical; current review incomplete
      H51-588A576EBD5D964F60A5CAD4preparation-assessments-v3.8.json
      /196/concentration_values_detected/1/high
      Historical; current review incomplete
      H51-3FDDB217BAEB3F00CC8B3826preparation-assessments-v3.8.json
      /196/concentration_values_detected/1/unit
      Historical; current review incomplete
      H51-A4E2046FE87F1CAEC7BF357Dpreparation-assessments-v3.8.json
      /196/concentration_values_detected/1/text
      Historical; current review incomplete
      H51-7B9C6432AC9ED72EDDA59D2Fpreparation-assessments-v3.8.json
      /196/source_files/0
      Historical; current review incomplete
      H51-EEFB0C3660A2B7FDF414F9FBpreparation-assessments-v3.8.json
      /196/source_files/1
      Historical; current review incomplete
      H51-C2E1D91E737A95B150CDD27Bpreparation-assessments-v3.8.json
      /196/source_files/2
      Historical; current review incomplete
      H51-6CE31E94CF874778864BE0BFpreparation-assessments-v3.8.json
      /196/clinical_release_note
      Historical; current review incomplete